Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN3500 with or without dupilumab in adults with moderate-to-severe atopic dermatitis
2018-001543-30Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing REGN3500 monotherapy, REGN3500 plus dupilumab combination and Placebo (3 arms). Primary endpoint: Percent change in EASI score from baseline to week 16. Started Feb 2019; status: terminated.
02
Drugs
itepekimabdupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-001543-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001543-30.